BofA lowered the firm’s price target on Karuna Therapeutics to $259 from $304 and keeps a Buy rating on the shares after offering updated views on key investor debates within the analyst’s CNS coverage. On further review, the firm says its prior Karuna KarXT schizophrenia forecasts were “too high,” but adds that it still views $3B in peak sales as “feasible” given the strength of the profile.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on KRTX:
- Karuna Therapeutics initiated with an Overweight at Wells Fargo
- Karuna Therapeutics price target lowered to $258 from $274 at Mizuho
- Karuna Therapeutics names Jason Brown as CFO, Jonathan Rosin as CHRO
- Karuna Therapeutics reports Q2 EPS ($2.75), consensus ($2.78)
- 3 Best Stocks to Buy Now, 7/20/2023, According to Top Analysts